Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of Insulin Like Growth Facror-1 Genetic Polymorphism with Gastric Cancer Susceptibility and Clinicopathological Features

  • Farahani, Roya Kishani (Basic and Molecular Epidemiology of Gastroenterology, Disease Research Center, Shahid Beheshti University of Medical Sciences) ;
  • Azimzadeh, Pedram (Basic and Molecular Epidemiology of Gastroenterology, Disease Research Center, Shahid Beheshti University of Medical Sciences) ;
  • Rostami, Elham (Basic and Molecular Epidemiology of Gastroenterology, Disease Research Center, Shahid Beheshti University of Medical Sciences) ;
  • Malekpour, Habib (Gastroenterology and Liver, Disease Research Center, Shahid Beheshti University of Medical Sciences) ;
  • Aghdae, Hamid Asadzadeh (Basic and Molecular Epidemiology of Gastroenterology, Disease Research Center, Shahid Beheshti University of Medical Sciences) ;
  • Pourhoseingholi, Mohamad Amin (Gastroenterology and Liver, Disease Research Center, Shahid Beheshti University of Medical Sciences) ;
  • Mojarad, Ehsan Nazemalhosseini (Gastroenterology and Liver, Disease Research Center, Shahid Beheshti University of Medical Sciences) ;
  • Zali, Mohammad Reza (Gastroenterology and Liver, Disease Research Center, Shahid Beheshti University of Medical Sciences)
  • Published : 2015.06.03
Download PDF
⟨ Previous Next ⟩

Abstract

Gastric cancer (GC) is one of the most common malignancies in the world. It is the first cause of cancer deaths in both sexes In Iranian population. Circulating insulin-like growth factor-one (IGF-1) levels have been associated for gastric cancer. IGF-1 protein has central roles involved in the regulation of epithelial cell growth, proliferation, transformation, apoptosis and metastasis. Single nucleotide polymorphism in IGF-1 regulatory elements may lead to alter in IGF-1expression level and GC susceptibility. The aim of this study was to investigate the influence of IGF-1 gene polymorphism (rs5742612) on risk of GC and clinicopathological features for the first time in Iranian population. In total, 241 subjects including 100 patients with GC and 141 healthy controls were recruited in our study. Genotypes were analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay with DNA from peripheral blood. The polymorphism was statistically analyzed to investigate the relationship with the risk of GC and clinicopathological properties. Logistic regression analysis revealed that there was no significant association between rs5742612 and the risk of GC. In addition, no significant association between genotypes and clinicopathological features was observed (p value>0.05). The frequencies of the CC, CT, and TT genotypes were 97%, 3%, and 0%, respectively, among the cases, and 97.9%, 2.1%, and 0%, respectively, among the controls. CC genotype was more frequent in cases and controls. The frequencies of C and T alleles were 98.9% and 1.1% in controls and 98.5% and 1.5% in patient respectively. Our results provide the first evidence that this variant is rare in Iranian population and it may not be a powerful genetic predisposing biomarker for prediction GC clinicopathological features in an Iranian population.

Keywords

References

  1. Altinkaynak K, Bilici M, Bakan N, Akcay F (2012). Circulating levels of IGF-I and IGFBP-3 in gastric cancer. Turk J Med Sci, 42, 1458-62.
  2. Arkani M, Safaei A, Karimi Kh, Mohsen Vahedi, et al (2012). Association of IGF-1 gene (rs5742612) polymorphism with colorectal cancer. J Sabzevar Univers Med Sc, 19, 109-15.
  3. Altinkaynak K, Bilici M, Bakan N, Akay F (2012). Circulating levels of IGF-I and IGFBP-3 in gastric cancer. Turk J Med Sci, 42, 1458-62.
  4. Chan JM, Stampfer MJ, Ma J, et al (2002). Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst, 94, 1099-106. https://doi.org/10.1093/jnci/94.14.1099
  5. Cheng I, Stram DO, Penney KL, et al (2006). Common genetic variation in IGF1 and prostate cancer risk in the multiethnic cohort. J Natl Cancer Inst, 98 ,123-34. https://doi.org/10.1093/jnci/djj013
  6. Chen W, Wang S, Tian T, et al (2009). Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. European J Human Genet, 17, 1668-75. https://doi.org/10.1038/ejhg.2009.86
  7. Delafontaine P, Song Y, Li Y (2004). Expression, Regulation, and Function of IGF-1, IGF-1R, and IGF-1 Binding Proteins in Blood Vessels. Arterioscler Thromb Vasc Biol, 24, 435-44. https://doi.org/10.1161/01.ATV.0000105902.89459.09
  8. D'Aloisio AA, JC Schroeder, Kari E, et al (2009). IGF-I and IGFBP-3 polymorphisms in relation to circulating levels among African American and Caucasian women. Cancer Epidemiol Biomarkers Prev, 18, 954-66. https://doi.org/10.1158/1055-9965.EPI-08-0856
  9. Feik E, Baierl A, Hieger B, et al (2010). Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk. Cancer Causes Control, 21, 91-7. https://doi.org/10.1007/s10552-009-9438-4
  10. Forman D, Burley V (2006). Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol, 20, 633-49. https://doi.org/10.1016/j.bpg.2006.04.008
  11. Furstenberger G, Senn HJ (2002). Insulin-like growth factors and cancer. Lancet Oncol, 3, 298-302. https://doi.org/10.1016/S1470-2045(02)00731-3
  12. Gao L, Nieters A, Brenner H (2009). Cell proliferation-related genetic polymorphisms and gastric cancer risk: systematic review and meta-analysis. European J Human Genet, 17, 1658-67. https://doi.org/10.1038/ejhg.2009.102
  13. Harrela M, Koistinen H, Kaprio J, et al (1996) Genetic and environmental components of interindividual variation in circulating levels of IGF-1, IGF-II, IGFBP-3. J Clin Invest, 98, 2612-15. https://doi.org/10.1172/JCI119081
  14. Karamouzis MV, Papavassiliou AG (2006). The IGF-1 network in lung carcinoma therapeutics. Trends Mol Med, 12, 595-602. https://doi.org/10.1016/j.molmed.2006.10.003
  15. Katoh T, Nagata N, Kuroda Y, et al (1996). Glutathione S-transferase M1(GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis, 17, 1855-9. https://doi.org/10.1093/carcin/17.9.1855
  16. Lukanova A, Lundin E, Toniolo P, et al (2002). Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer, 101, 549-54. https://doi.org/10.1002/ijc.10613
  17. Lukanova A, Lundin E, Micheli A, et al (2003). Risk of ovarian cancer in relation to prediagnostic levels of C-peptide, insulinlike growth factor binding proteins-1 and -2 (USA, Sweden, Italy). Cancer Causes Control, 14, 285-92. https://doi.org/10.1023/A:1023688603547
  18. Lacey JV, Potischman N, Madigan MP, et al (2004). Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a US case-control study. Cancer Epidemiol Biomarkers Prev, 13, 607-12.
  19. Lian H, Zhou Y, Jian Z, Liu R (2014). MiR-323-5p acts as a tumor suppressor by targeting the insulin-like growth factor 1 receptor in human glioma cells. Asian Pac J Cancer Prev, 15, 10181-85.
  20. McLean MH, El-Omar EM (2014). Genetics of gastric cancer. Nature Rev Gastroenterol Hepatol, 11, 664-74. https://doi.org/10.1038/nrgastro.2014.143
  21. Malekzadeh R, Derakhshan MH, Malekzadeh Z (2009). Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med, 12, 576-83.
  22. Miller S, Dykes D, Polesky H (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 16, 1215. https://doi.org/10.1093/nar/16.3.1215
  23. Ma J, Pollak MN, Giovannucci E, et al (1999). Prospective study of colorectal cancer risk in men and plasma levels of insulinlike growth factor (IGF)-I and IGFbinding protein-3. J Natl Cancer Inst, 91, 620-5. https://doi.org/10.1093/jnci/91.7.620
  24. Nakao M, Hosono S , Ito H , et al (2011). Interaction between IGF-1 polymorphisms and overweight for the risk of pancreatic cancer in Japanese. Int J Mol Epidemiol Genet, 2, 354-66.
  25. Pollak M (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer, 8, 915-28. https://doi.org/10.1038/nrc2536
  26. Qian J, Zhou H, Chen J, et al (2014). Genetic polymorphisms in IGF-I and IGFBP-3 are associated with prostate cancer in the Chinese population. Plos one, 9, 85609-15. https://doi.org/10.1371/journal.pone.0085609
  27. Rostami M, Kadivar M, Aznab M, Abachi M (2011). Influence of age and gender on association between-765G> C COX-2 genetic polymorphism and gastric adenocarcinoma risk: a case-control study in Iran. Gastroenterol Hepatol Bed Bench, 5, 29-3.
  28. Smith MG, Hold GL, Tahara E, El-Omar EM (2006). Cellular and molecular aspects of gastric cancer. World J Gastroenterol, 12, 2979-90. https://doi.org/10.3748/wjg.v12.i19.2979
  29. Setiawan VW, Zhang ZF, Yu GP, et al (2000). GSTT1 and GSTM1 null genotypes and the risk of gastric cancer: a case-control study in a Chinese population. Cancer Epidemiol Biomarkers Prev, 9, 73-80.
  30. Stadtlander CTH (1999). Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis, 20, 2195-208. https://doi.org/10.1093/carcin/20.12.2195
  31. Samani AA, Yakar S, LeRoith D, et al (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev, 28, 20-47. https://doi.org/10.1210/er.2006-0001
  32. Shitara K, Ito S, Misawa K, et al (2011). Genetic polymorphism of IGF-I predicts recurrence in patients with gastric cancer who have undergone curative gastrectomy. Ann Oncol, 23, 659-64.
  33. Setiawan VW, Cheng I, Stram DO, et al (2006). Igf-I genetic variation and breast cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev, 15, 172-4. https://doi.org/10.1158/1055-9965.EPI-05-0625
  34. Tong D, Wen X, Jin Y, et al (2010). Changes of androgen receptor and insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide. Asian Pac J Cancer Prev, 11, 1805-9.
  35. Tsugane S, Inoue M (2010). Insulin resistance and cancer: epidemiological evidence. Cancer Sci, 101, 1073-79. https://doi.org/10.1111/j.1349-7006.2010.01521.x
  36. Tao Y, Pinzi V, Bourhis J, Deutsch E (2007). Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol, 4, 591-602.
  37. Wong HL, Delellis K, Probst-Hensch N, et al (2005). A new single nucleotide polymorphism in the insulin-like growth factor I regulatory region associates with colorectal cancer risk in Singapore chinese. Cancer Epidemiol Biomarkers Prev, 14, 144-51.
  38. Wolk A, Mantzoros CS, Andersson SO, et al (1998). Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst, 90, 911-5. https://doi.org/10.1093/jnci/90.12.911
  39. Yu H, Rohan T (2000). Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst J, 92, 1472-89. https://doi.org/10.1093/jnci/92.18.1472
  40. Yang H, Qu R, Lin X , et al (2014). IGF-1 from adipose-derived mesenchymal stem cells promoes radioresistance of breast cancer cells. Asian Pac J Cancer Prev, 15, 10115-9.

Cited by

  1. Body mass index, serum total cholesterol, and risk of gastric high-grade dysplasia vol.95, pp.35, 2016, https://doi.org/10.1097/MD.0000000000004730
  2. variants with lymph node status and esophagogastric junction adenocarcinoma risk pp.07302312, 2018, https://doi.org/10.1002/jcb.27834